Prostate Cancer: Overdiagnosis in Solid Organ Transplant Recipients
Overall incidence of prostate cancer decreased between 2003 and 2017.
Prostate Cancer News
PROSTATE CANCER ADVISOR
Prostate Cancer News
Targeted Therapies, Immunotherapies, Immunomodulators: A Quick Guide to Cancer Therapy Descriptions
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
No Higher Death Risk for Black Men on Active Surveillance for Low-Risk PCa
At 7.6 years, prostate cancer-specific and all-cause mortality were not significantly different among Black and White veterans.
Study Supports Salvage Over Adjuvant RT After Prostate Surgery
Initial results from the RADICALS-RT study do not support routine administration of adjuvant radiation therapy after radical prostatectomy in patients at elevated risk for prostate cancer recurrence.
Prostate Cancer SBRT Offers ‘Excellent’ Long-Term Oncologic Control
Stereotactic body radiation therapy for localized prostate cancer is associated with high 12-year rates of biochemical disease-free survival.
Localized Prostate Cancer Incidence Declines, Distant Stage Rises
Although fewer men are being diagnosed with localized prostate cancer, more are being diagnosed with distant-stage disease.
Fluciclovine PET/CT Improves Prostate Cancer Salvage Radiation Outcomes
Fluciclovine PET/CT plus conventional imaging vs conventional imaging alone to guide radiation therapy for men with recurrent PCa following radical prostatectomy results in improved failure-free survival, according to the first randomized trial comparing the 2 approaches.
Black Men Have Better Outcomes From Radiation-Based Tx for High-Risk PCa
Black race is associated with improved oncologic outcomes among men undergoing radiation-based therapy for high-risk prostate cancer, new findings suggest.
Circulating Tumor Cells May Predict Response to Radium-223 in mCRPC
Pretreatment counts of 5 CTCs per 7.5 mL of blood or higher correlated with shorter survival compared with lower counts among men with metastatic castration-resistant prostate cancer treated with radium-223, a study found.
Understanding the Stigma Experienced by Patients With Prostate Cancer
Interview study reveals men’s perception and concerns related to their prostate cancer journey.
Reliability of Laboratory-Developed Tests Called Into Question
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
Immunotherapy in mCRPC: Teasing Out the Right Dosing Schedule
The phase 2 Clinical Trial CheckMate 650 shows promise for some immunotherapy in subset of patients with advanced prostate cancer, but the toxicities are concerning.
Radiation for Abdominal, Pelvic Cancers Ups Secondary Sarcoma Risk
Compared with patients who undergo surgery alone for abdominal or pelvic cancers, those who receive radiation and chemotherapy are at elevated risk for secondary sarcomas.
Black Men With Prostate Cancer Found to Be Reluctant to Participate in Trials
Efforts should be made to address patient concerns about clinical trial participation.
Greater Subcutaneous Fat Improves mCRPC Treatment Response
In a study of men with mCRPC receiving chemotherapy and maximal androgen ablation, those who had an objective response to treatment had a significantly higher subcutaneous adipose tissue index than those who did not.
How the Coronavirus Pandemic May Affect Cancer Clinical Trials
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
With Rucaparib Approval, Prostate Cancer Joins the Precision Oncology Era
The FDA’s accelerated approval of the PARP inhibitor rucaparib brings clinical prostate oncology into the precision medicine era.
Earlier Surrogate for Survival After RP Relapse Possibly Identified
Castration-resistant prostate cancer correlates strongly with development of metastasis in men with PSA relapse following radical surgery for localized prostate cancer, but it occurs much sooner, and thus may provide an intermediate endpoint in clinical trials of new therapeutics.
PARP Inhibitor Prolongs Overall Survival in mCRPC
An overall survival advantage with olaparib was particularly observed among patients with BRCA1 or BRCA2 alterations.
Radiologic PFS Benefit Observed for Addition of AKT Inhibitor to Abiraterone in Metastatic CRPC
Loss of the tumor suppressor PTEN, a negative prognostic factor in metastatic CRPC, is associated with dysregulation of the PI3K–AKT–mTOR pathway.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
